Your browser doesn't support javascript.
loading
Determination of Unbound Partition Coefficient and in Vitro-in Vivo Extrapolation for SLC13A Transporter-Mediated Uptake.
Riccardi, Keith; Li, Zhenhong; Brown, Janice A; Gorgoglione, Matthew F; Niosi, Mark; Gosset, James; Huard, Kim; Erion, Derek M; Di, Li.
Afiliación
  • Riccardi K; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Li Z; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Brown JA; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Gorgoglione MF; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Niosi M; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Gosset J; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Huard K; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Erion DM; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.).
  • Di L; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT (K.R., J.A.B., M.N., L.D.); Cambridge, MA (M.F.G., J.G., K.H., D.M.E.) Li.Di@Pfizer.Com.
Drug Metab Dispos ; 44(10): 1633-42, 2016 10.
Article en En | MEDLINE | ID: mdl-27417179
ABSTRACT
Unbound partition coefficient (Kpuu) is important to an understanding of the asymmetric free drug distribution of a compound between cells and medium in vitro, as well as between tissue and plasma in vivo, especially for transporter-mediated processes. Kpuu was determined for a set of compounds from the SLC13A family that are inhibitors and substrates of transporters in hepatocytes and transporter-transfected cell lines. Enantioselectivity was observed, with (R)-enantiomers achieving much higher Kpuu (>4) than the (S)-enantiomers (<1) in human hepatocytes and SLC13A5-transfected human embryonic 293 cells. The intracellular free drug concentration correlated directly with in vitro pharmacological activity rather than the nominal concentration in the assay because of the high Kpuu mediated by SLC13A5 transporter uptake. Delivery of the diacid PF-06649298 directly or via hydrolysis of the ethyl ester prodrug PF-06757303 resulted in quite different Kpuu values in human hepatocytes (Kpuu of 3 for diacid versus 59 for prodrug), which was successfully modeled on the basis of passive diffusion, active uptake, and conversion rate from ester to diacid using a compartmental model. Kpuu values changed with drug concentrations; lower values were observed at higher concentrations possibly owing to a saturation of transporters. Michaelis-Menten constant (Km) of SLC13A5 was estimated to be 24 µM for PF-06649298 in human hepatocytes. In vitro Kpuu obtained from rat suspension hepatocytes supplemented with 4% fatty acid free bovine serum albumin showed good correlation with in vivo Kpuu of liver-to-plasma, illustrating the potential of this approach to predict in vivo Kpuu from in vitro systems.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas de Transporte de Catión / Simportadores Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas de Transporte de Catión / Simportadores Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article